Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

merck sharp & dohme b.v. - aprepitant - vomiting; postoperative nausea and vomiting; cancer - antiemetics and antinauseants, - emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (ponv) in adults.emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate summary of product characteristics).emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.emend 80 mg, 125 mg, 165 mg hard capsules and emend powder for oral suspension are given as part of combination therapy.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - imatinib, quantity: 100 mg (equivalent: imatinib mesilate, qty 119.5 mg) - tablet, film coated - excipient ingredients: crospovidone; hypromellose; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; purified talc; iron oxide yellow; macrogol 4000; iron oxide red - glivec is indicated for the: -treatment of patients with chronic myeloid leukaemia (cml). -treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. -treatment of adult patients with relapsed or refractory ph+ all as monotherapy. -treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed. -treatment of adult patients with aggressive systemic mastocytosis (asm) where conventional therapies have failed. treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). -treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) -adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) . -treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp) glivec is indicated for the: -treatment of patients with chronic myeloid leukaemia (cml). -treatment of adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. -treatment of adult patients with relapsed or refractory ph+ all as monotherapy. -treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed. -treatment of adult patients with aggressive systemic mastocytosis (asm) where conventional therapies have failed. treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). -treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) -adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials). -treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

boston scientific pty ltd - 45664 - embolization implant, chemotherapeutic - dc bead lumi is a hydrogel bead, which is radiopaque, biocompatible, hydrophilic, non resorbable, size calibrated and capable of loading and eluting doxorubicin or irinotecan prior to embolisation and then as a secondary action, elute a local, controlled and sustained dose to the tumour after embolization. the drugs are not supplied with the device. dc bead lumi? can be used as an embolic agent with or without delivery of doxorubicin or irinotecan. unloaded dc bead lumi? is intended to be used for the embolisation of non-malignant hypervascular tumors and arteriovenous malformations (avms).dc bead lumitm is primarily intended as an embolic agent for the local treatment of malignant hypervascularised tumour(s) in the liver. dc bead lumitm is compatible with doxorubicin for the local treatment of tumours in patients with hepatocellular carcinoma. doxorubicin can be loaded prior to embolisation and, as a secondary action, the beads will elute a local, controlled and sustained dose to the tumour after embolisation. dc bead lumitm is also intended to embolise the vessels supplying malignant colorectal cancer metastasised to the liver (mcrc). dc bead lumitm is compatible with irinotecan which can be loaded prior to embolisation and then, as a secondary action, the beads will elute a local, controlled and sustained dose to the mcrc after embolisation.

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chemo iberica s.a. - benazepril 4,6 mg - eq. benazepril hydrochloride 5 mg - film-coated tablet - 5 mg - benazepril hydrochloride 5 mg - benazepril - dog

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chemo iberica s.a. - benazepril 18,42 mg - eq. benazepril hydrochloride 20 mg - film-coated tablet - 20 mg - benazepril hydrochloride 20 mg - benazepril - dog

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dacarbazine, quantity: 200 mg - injection, powder for - excipient ingredients: mannitol; citric acid monohydrate - chemotherapy of metastatic malignant melanoma and various sarcomas. in other cancers, the available evidence shows dacarbazine to be ineffective or less effective than established regimens. note: the use of dacarbazine is restricted to hospitals with an oncology service.

Բանգլադեշ - անգլերեն - DGDA (Directorate General of Drug Administration)

chemist laboratories ltd. - vitamin c - injection - 500 mg/5 ml

Բանգլադեշ - անգլերեն - DGDA (Directorate General of Drug Administration)

chemist laboratories ltd. - vitamin c - tablet - 250 mg

Պանամա - անգլերեն - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

chemo centroamericana,s.a - sulfasalazina - sulfasalazina....500.00 mg